26 completed, 12 recruiting, 8 active not recruiting, 6 terminated. 27 Phase 2, 20 Phase 1, 6 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Fallopian Tube Carcinoma: new trials by email Literature Review of Fallopian Tube Carcinoma trials Research Report on Fallopian Tube Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 2 | Recruiting | University of Washington | 26 | 2026-09-16 | 2026-11-02 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-01 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-02-04 | 2026-03-18 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer SCT-001 CAR-T cells - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 1 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 24 | 2025-06-01 | 2025-02-26 |
| REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors REVITALIZE Intervention, Educational Materials - Ovarian Cancer, Advanced Ovarian Carcinoma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 240 | 2025-03-17 | 2026-04-13 |
| Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment Non-Interventional Study - Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection | Completed | Mayo Clinic | 49 | 2025-03-07 | 2025-12-04 | |
| Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers Best Practice, Cilostazol, Cryocompression Therapy - Cervical Carcinoma, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Emory University | 70 | 2024-08-01 | 2026-08-27 |
| RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression RC48+carboplatin±bevacizumab - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 54 | 2024-05-16 | 2026-10-01 |
| NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NM32-2668 - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Terminated | Numab Therapeutics AG | 11 | 2024-05-01 | 2025-07-23 |
| Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery Acute Normovolemic Hemodilution/ANH - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-02-23 | 2026-04-01 |
| Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy AHCC, Chemotherapy, Placebo - Ovarian Epithelial Carcinoma, Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | University of California, Davis | 20 | 2023-08-01 | 2026-03-12 |
| Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer Cisplatin 100 mg/m2, Cisplatin 40 mg/l - FIGO Stage III Ovarian Cancer, Peritoneal Cancer | Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 40 | 2022-06-15 | 2025-07-20 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation Guardant Reveal - Bladder Carcinoma, Ureter Carcinoma | Recruiting | Guardant Health, Inc. | 2285 | 2021-09-07 | 2026-09-14 | |
| A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care DCVAC/OvCa, Placebo - Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 2 | Recruiting | Peking University Third Hospital | 75 | 2021-04-19 | 2021-05-03 |
| National Cancer Institute "Cancer Moonshot Biobank" Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8 | Active not recruiting | National Cancer Institute (NCI) | 1600 | 2020-11-11 | 2026-10-05 | |
| Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy Prehabilitation - Ovarian Cancer, Stage III Ovarian Cancer | Not applicable | Active not recruiting | Memorial Sloan Kettering Cancer Center | 22 | 2019-12-16 | 2026-01-07 |
| Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives Interview, Questionnaire Administration, Survey Administration - Breast Carcinoma, Deleterious CDH1 Gene Mutation | Completed | M.D. Anderson Cancer Center | 46 | 2019-08-21 | 2024-07-12 | |
| Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace - Breast Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 300 | 2018-12-18 | 2026-10-06 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors XmAb20717 - Melanoma, Breast Carcinoma | Phase 1 | Completed | Xencor, Inc. | 150 | 2018-07-10 | 2022-12-01 |
Showing 20 of 62. Sign in to see all of them.
Fallopian Tube Neoplasms (62) · Ovarian Neoplasms (52) · Carcinoma, Ovarian Epithelial (11) · Endometrial Neoplasms (7) · Melanoma (6) · Breast Neoplasms (5) · Brenner Tumor (5) · Carcinoma, Renal Cell (5) · Recurrence (5) · Triple Negative Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Uterine Cervical Neoplasms (4) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Prostatic Neoplasms (3)
Adnexal Diseases (62) · Fallopian Tube Diseases (62) · Female Urogenital Diseases (62) · Female Urogenital Diseases and Pregnancy Complications (62) · Genital Diseases (62) · Genital Diseases, Female (62) · Genital Neoplasms, Female (62) · Neoplasms (62) · Neoplasms by Site (62) · Urogenital Diseases (62) · Urogenital Neoplasms (62) · Endocrine Gland Neoplasms (58) · Endocrine System Diseases (58) · Gonadal Disorders (58) · Ovarian Diseases (58)
Carboplatin (11) · Paclitaxel (9) · Taxes (8) · Cisplatin (7) · Magnetic Resonance Spectroscopy (5) · Bevacizumab (4) · Cyclophosphamide (4) · Hyperthermic Intraperitoneal Chemotherapy (4) · Specimen Handling (4) · Cytoreduction Surgical Procedures (3) · Platinum (3) · olaparib (3) · Biopsy (2) · Chemotherapy, Adjuvant (2) · Disulfides (2)
Gynecologic Oncology Group (12) · National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (4) · Beijing Biotech (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · Roswell Park Cancer Institute (2) · Shanghai Gynecologic Oncology Group (2) · The University of Texas Health Science Center at San Antonio (2) · Advenchen Laboratories, LLC (1) · Aivita Biomedical, Inc. (1) · Cantonal Hospital of St. Gallen (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · European Institute of Oncology (1)
United States (47) · China (7) · Italy (4) · Spain (3) · Canada (2) · South Korea (2) · Belgium (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · Puerto Rico (1) · Switzerland (1) · United Kingdom (1)
Emese Zsiros, MD (2) · Joyce F Liu (2) · Robert Edwards (2) · Akira Hirasawa, M.D., Ph.D. (1) · Alexi A Wright, MD, MPH (1) · Amanika Kumar, MD (1) · Amina Ahmed (1) · Amit Oza (1) · Amy Tiersten (1) · Anil Sood (1) · Armando Sardi, M.D. (1) · Aung Naing, MD (1) · Charles P Theuer, MD (1) · Claudio Zamagni, MD (1)
PMID 37185961, PMID 23810467, PMID 25218906, PMID 31069579, PMID 31708167, PMID 33610319, PMID 33705695, PMID 33909232, PMID 34055086, PMID 34562230, PMID 34965890, PMID 35130043, PMID 37129197, PMID 38824243, PMID 39208372, PMID 39379328, PMID 39816915, PMID 39945382, PMID 41928160
U10CA027469 (10), U10CA101165 (4), U10CA180868 (3), UM1CA186709 (2), N01CM00071 (1), N01CM17107 (1), N01CM62203 (1), P30CA006516 (1), P30CA016056 (1), P30CA138292 (1), P50CA136393 (1), R01CA249329 (1), R01CA289547 (1), U01CA062490 (1), UG1CA189867 (1)